

IFW



LEOPOLD PRESSER  
FRANK S. DIGIGLIO  
PAUL J. ESATTO, JR.  
JOHN S. SENSNY  
MARK J. COHEN  
EDWARD W. GROLZ  
STEVEN FISCHMAN  
PETER I. BERNSTEIN  
THOMAS SPINELLI

ROBERT L. BERNSTEIN  
MARVIN BRESSLER  
DERMOTT J. COOKE\*  
RICHARD J. DANYKO  
BRADLEY M. MARAZAS  
SETH M. WEINFELD  
KEITH A. WELTSCH\*  
YONGZHI YANG\*  
XIAOCHUN ZHU

\*OH BAR ONLY

\*MD BAR ONLY

\*NC BAR ONLY

YONG LU  
LESLIE S. SZIVOS, PH.D.  
DAVID J. TORRENTE, J.D.  
PATENT AGENTS

DOMINICK A. TUCCIO  
TECHNICAL COUNSULTANT

SCULLY, SCOTT, MURPHY & PRESSER  
A PROFESSIONAL CORPORATION  
ATTORNEYS AT LAW  
400 GARDEN CITY PLAZA, SUITE 300  
GARDEN CITY, NEW YORK 11530-3319

ALLEN R. MORGANSTERN  
ALEX P. SZECSY  
STEPHEN A. YOUNG  
COUNSEL

ZHUANG YUAN  
TECHNICAL CONSULTANT

JOHN F. SCULLY  
STEPHEN D. MURPHY  
KENNETH L. KING  
RETIRED

ANTHONY C. SCOTT (1931-1994)  
WILLIAM E. McNULTY (1927-1993)

TELEPHONE: (516) 742-4343

FACSIMILE: (516) 742-4366

E-MAIL: Intprop@ssmp.com

January 13, 2006

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Re: USSN: 10/500,606  
Maria Cristina Geroni, et al.  
Our Docket: 17703

Dear Sirs:

The Filing Receipt for the above-identified patent application does not list the Assignment For Published Patent Application information. It should read as follows:

**Assignment For Published Patent Application**  
**Pharmacia Italia SPA, Milan, Italy**

as indicated on the enclosed pages. Please make the corrections and send us a corrected Filing Receipt.

Very truly yours,

*Scully, Scott, Murphy & Presser*  
Scully, Scott, Murphy & Presser

SSM&P/tw  
Encl.



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/500,606	05/05/2005	1614	1348	17703 (PC27210A)		27	5

CONFIRMATION NO. 4724

Peter I Bernstein  
 Scully Scott, Murphy & Presser  
 400 Garden City Plaza  
 Suite 300  
 Garden City, NY 11530

## FILING RECEIPT



\*OC000000017739258\*

Date Mailed: 12/29/2005

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Maria Cristina Geroni, Milan, ITALY;  
 Camilla Fowst, Milan, ITALY;  
 Paolo Cozzi, Milan, ITALY;

*Assignment For Published Patent Application*  
*Pharmacia Italia SPA, Milan, Italy*

## Power of Attorney:

Leopold Presser--19827  
 William Roch--24972  
 John Sensny--28757  
 Paul Esatto--30749  
 Frank DiGiglio--31346

Mark Cohen--32211  
 Edward Grolz--33705  
 Steven Fischman--34594  
 Thomas Spinelli--39533  
 Peter Bernstein--43497

## Domestic Priority data as claimed by applicant

This application is a 371 of PCT/EP02/13092 12/18/2002

## Foreign Applications

EUROPEAN PATENT OFFICE (EPO) 02075052.7 01/02/2002

Projected Publication Date: 04/06/2006

Non-Publication Request: No

Early Publication Request: No

**Title**

Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and protein kinase (serine/threonine kinase) inhibitors

**Preliminary Class**

514

**PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES**

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

---

**LICENSE FOR FOREIGN FILING UNDER****Title 35, United States Code, Section 184****Title 37, Code of Federal Regulations, 5.11 & 5.15****GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted

under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

#### **NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

## TRANSMITTAL LETTER TO THE UNITED STATES

DESIGNATED/ELECTED OFFICE (DO/EO/US)

CONCERNING A FILING UNDER 35 U.S.C. 371

17703 (PC27210A)

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

INTERNATIONAL APPLICATION NO.  
PCT/EP02/13092INTERNATIONAL FILING DATE  
18 December 2002 (18.12.2002)PRIORITY DATE CLAIMED  
2 January 2002 (02.01.2002)

## TITLE OF INVENTION

COMBINED THERAPY AGAINST TUMORS COMPRISING SUBSTITUTED ACRYLOYL DISTAMYCIN  
DERIVATIVES AND PROTEIN KINASE (SERINE/THREONINE KINASE) INHIBITORS

## APPLICANT(S) FOR DO/EO/US

Maria Geroni, Camilla Fowst and Paolo Cozzi

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.
4. ☒ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
  - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
  - b. ☒ has been communicated by the International Bureau.
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
  - a. ☐ is attached hereto.
  - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
  - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
  - b. ☐ have been communicated by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
10. ☐ An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).
11. ☒ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☒ A copy of the International Search Report (PCT/ISA/210).

## Items 13 to 20 below concern document(s) or information included:

13. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☐ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
20. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
21. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
22. ☒ Express Mail Label No. EV213901318US
23. ☒ Other items or information:

Courtesy copy of International Application

Assignee: PHARMACIA ITALIA SPA of Milan, Italy

ASSIGNMENT

WHEREAS, we, **Maria Cristina Geroni, Camilla Fowst and Paolo Cozzi** are joint inventors of "**COMBINED THERAPY AGAINST TUMORS COMPRISING SUBSTITUTED ACRYLOYL DISTAMYCIN DERIVATIVES AND PROTEIN KINASE (SERINE/THREONINE KINASE) INHIBITORS**" application for United States Letters Patent Application Serial No. **10/500,606**, filed **June 30, 2004**; and

WHEREAS, **Pharmacia Italia S.p.A.**, a corporation created and existing under and by virtue of the laws of the country of Italy, is desirous of acquiring the entire right, title and interest in and to the aforesaid invention throughout the world, and all right, title and interest in, to and under any and all Letters Patent of the United States and all other countries throughout the world;

NOW, THEREFORE, for and in consideration of the sum of One Dollar (\$1.00) to us in hand paid by **Pharmacia Italia S.p.A.** and for other good and valuable considerations, the receipt of which is hereby acknowledged, we hereby sell, assign, transfer and set over to **Pharmacia Italia S.p.A.**, all right, title and interest in and to the said invention throughout the world, and said application for United States Letters Patent, and any and all divisions, continuations, reexaminations and reissues thereof, and any and all Letters Patent of the United States and foreign countries which may be granted therefore, the same to be held and enjoyed by **Pharmacia Italia S.p.A.** for its own use and benefit, and for the use and benefit of its successors, assigns, or other legal representatives, to the end of the term or terms for which said Letters Patent of the United States or foreign countries are or may be granted, reexamined or reissued, as fully

05-09-2005

Jcket No.: 17703 (PC27210A)

U.S. DEPARTMENT OF COMMERCE  
Patent and Trademark Office

Tab settings → → →

To the Director of the United States Patent and Trademark Office. Please record the attached original documents or copy thereof.

1. Name of conveying party(ies):

**Maria Cristina Geroni**  
**Camilla Fowst**  
**Paolo Cozzi**

2. Name and address of receiving party(ies):

Name: **Pharmacia Italia S.p.A.**

Address: **Via Robert Koch 1.2**

Additional names(s) of conveying party(ies) attached? ☐ Yes ☒ No

3. Nature of conveyance:

- ☒ Assignment ☐ Merger  
☐ Security Agreement ☐ Change of Name  
☐ Other

City: **Milan** State/Prov.:  
Country: **Italy** ZIP: **20152**

Execution Date: **March 16, 2005**

Additional name(s) & address(es) attached? ☐ Yes ☒ No

4. Application number(s) or patent numbers(s):

If this document is being filed together with a new application, the execution date of the application is:

Patent Application No. Filing date  
**10/500,606** **June 30, 2004**

B. Patent No.(s)

05/06/2005 GTDN11 00000076 10500606

01 FC:8021

(40.00 DP)

Additional numbers attached? ☐ Yes ☒ No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: **Peter I. Bernstein**

Registration No. **43,497**

Address: **Scully, Scott, Murphy & Presser**

**400 Garden City Plaza, Suite 300**

City: **Garden City** State/Prov.: **NY**

Country: **USA** ZIP: **11530**

6. Total number of applications and patents involved: **1**

7. Total fee (37 CFR 3.41):.....\$ **40.00**

- ☒ Enclosed - Any excess or insufficiency should be credited or debited to deposit account  
☐ Authorized to be charged to deposit account

8. Deposit account number:

**19-1013/SSMP**

(Attach duplicate copy of this page if paying by deposit account)

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

**Peter I. Bernstein**

Name of Person Signing

Signature

**May 3, 2005**

Date

Total number of pages including cover sheet, attachments, and document: **4**